Esthesioneuroblastoma: IPOLFG 15 Years Experience

Authors

  • Margarida Boavida Interno do Complementar do Serviço de Otorrinolaringologia do Hospital Prof. Doutor Fernando Fonseca
  • Inês Delgado Interno do Complementar do Serviço de Otorrinolaringologia do Hospital Prof. Doutor Fernando Fonseca
  • Rui Cabral Interno do Complementar do Serviço de Otorrinolaringologia do Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental
  • Isabel Correia Interno do Complementar do Serviço de Otorrinolaringologia do Hospital de São José, Centro Hospitalar Lisboa Central
  • Luís Oliveira Assistente de Otorrinolaringologia do Instituto Português de Oncologia de Lisboa Francisco Gentil
  • Pedro Montalvão Chefe do Serviço de Otorrinolaringologia do Instituto Português de Oncologia de Lisboa Francisco Gentil
  • Miguel Magalhães Director do Serviço de Otorrinolaringologia do Instituto Português de Oncologia de Lisboa Francisco Gentil

DOI:

https://doi.org/10.34631/sporl.338

Keywords:

Esthesioneuroblastoma, modified Kadish staging system

Abstract

Objective: The aim of this study is to analyze clinicopathological findings, treatment and outcomes of esthesioneuroblastoma.

Material and methods: We performed a retrospective review of 18 consecutive patients with ENB diagnosis treated in a cancer reference center between 1999 and 2014.

Results: The mean age was 56 years old and 61% patients were female. According to the modified Kadish staging system, there were 5 stage B patients, 12 stage C patients and 1 stage D patient. Twelve patients were initially treated with surgery and adjuvant radiotherapy, 2 with surgery and adjuvant chemoradiotherapy, 3 with radiotherapy alone (1 of them palliative) and 1 with chemotherapy alone (palliative). The Kaplan Meier analysis estimated a survival of 76% at two years follow-up and 59% at five years follow-up.

Conclusions: In this study, patients with less advanced Kadish stage or who underwent surgery had a greater disease-free survival.

Downloads

Download data is not yet available.

References

Spiro JD, Soo KC, Spiro RH. Nonsquamous cell malignant neoplasms of the nasal cavities and paranasal sinuses. Head Neck. 1995 Mar-Apr;17(2):114-8.

Somenek M. Esthesioneuroblastoma. Medscape. Apr 2015.

Deniz T, Ozcan Y, Fatih S et al., “Olfactory Neuroblastomas: An Experience of 24 Years,” ISRN Oncology, vol. 2011, Article ID 451086, 7 pages, 2011. doi:10.5402/2011/451086.

Modesto A, Blanchard P, Tao YG, Rives M, Janot F, Serrano E, Benlyazid A, Guigay J, Ferrand FR, Delord JP, Bourhis J, Daly-Schveitzer N. Multimodal treatment and long-term outcome of patients with esthesioneuroblastoma. Oral Oncol. 2013 Aug;49(8):830-4. doi: 10.1016/j.oraloncology.2013.04.013. Epub 2013 Jun 5.

Eich HT, Hero B, Staar S, Micke O, Seegenschmiedt H, Mattke A, Berthold F, Müller RP. Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma. Strahlenther Onkol. 2003 Apr;179(4):233-40.

El Kababri M, Habrand JL, Valteau-Couanet D, Gaspar N, Dufour C, Oberlin O. Esthesioneuroblastoma in children and adolescent: experience on 11 cases with literature review. J Pediatr Hematol Oncol. 2014 Mar;36(2):91-5. doi:10.1097/MPH.0000000000000095.

Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001 Nov;2(11):683-90.

Published

2016-03-04

How to Cite

Boavida, M., Delgado, I., Cabral, R., Correia, I., Oliveira, L., Montalvão, P., & Magalhães, M. (2016). Esthesioneuroblastoma: IPOLFG 15 Years Experience. Portuguese Journal of Otorhinolaryngology and Head and Neck Surgery, 53(4), 251–254. https://doi.org/10.34631/sporl.338